InspireMD Announces Upcoming CFO Transition and Future Growth
InspireMD, Inc. has made a significant announcement regarding the impending retirement of its Chief Financial Officer, Craig Shore. This decision comes as the company prepares for a transition that aims to sustain its momentum as a developer of innovative medical technologies, particularly the CGuard™ Embolic Prevention Stent System (EPS), which plays a crucial role in stroke prevention.
Details of the CFO Transition
Craig Shore, who has been an integral part of InspireMD for 15 years, has communicated his decision to retire once a suitable successor is appointed. Mr. Shore will continue to serve in his role until that appointment is made, ensuring a smooth handover of responsibilities. Marvin Slosman, the Chief Executive Officer of InspireMD, expressed his gratitude for Craig's contributions, noting how integral he has been to the company's growth and his efforts to establish the organization as a leader in carotid intervention.
Marvin Slosman's Remarks
In a heartfelt statement, Slosman articulated, "Craig has served the company with unwavering dedication, and his leadership has been vital as we work toward potential U.S. FDA approval. His decision to retire speaks to his confidence in our future and his understanding of the evolving needs of our business. The Board of Directors and I deeply appreciate his significant contributions over the years.”
Craig Shore's Perspective
Reflecting on his tenure, Mr. Shore remarked, "It has been a fantastic journey to witness InspireMD evolve from a startup to a prominent player in the field of carotid intervention and stroke prevention. I trust that the company is well-equipped for the future and I eagerly anticipate the next chapter of my life while cherishing my time spent here."
The Search for a New CFO
In light of this transition, InspireMD has commenced its search for a new Chief Financial Officer. This search is crucial, as the company aims to maintain its growth trajectory and continue delivering on its strategic objectives, especially related to regulatory approvals and product development efforts.
About InspireMD, Inc.
InspireMD is committed to revolutionizing carotid stenting through its proprietary MicroNet technology, striving to set new industry standards. This innovative approach aims to deliver exceptional acute outcomes while ensuring long-term, stroke-free patient results. The company's stock is publicly traded on Nasdaq under the ticker symbol NSPR, reflecting its ongoing commitment to transparency and investor engagement.
Investor Relations
For investors and stakeholders, InspireMD routinely shares vital updates and relevant information through its corporate channels. The company emphasizes heightened transparency in its communications, indicating a robust approach to investor relations.
Frequently Asked Questions
What prompted Craig Shore's retirement?
Craig Shore decided to retire after 15 years, confident in InspireMD's future and ensuring a smooth transition for his successor.
Who will be the next CFO of InspireMD?
InspireMD is currently searching for a new Chief Financial Officer to fill Craig Shore's position, with a focus on leadership continuity.
What is InspireMD known for?
InspireMD is known for its CGuard™ Embolic Prevention Stent System, aimed at preventing strokes and enhancing carotid interventions.
What is the significance of the MicroNet technology?
MicroNet is designed to set the industry standard for carotid stenting, providing exceptional short-term and long-term patient outcomes.
How can investors stay updated with InspireMD?
Investors can stay updated by regularly visiting InspireMD's official website and following their announcements through official channels.
